This study aimed to identify novel ovarian cancer biomarkers and potential therapeutic targets through molecular analysis of tumor vascular cells.
INTRODUCTION
Gene expression profiling is a convenient method to uncover tumor-specific genes that may function as biomarkers or therapeutic targets. So far, important efforts have been made regarding the cancer cell as the main source of biomarkers.
1,2 However, emerging studies argue that tumor components other than tumor cells may contribute significantly to cancer molecular signatures. In landmark studies, tumor neovessels have been shown to be different from vessels of normal tissues, 3 expressing unique genes. 4, 5 Cellular and molecular changes characterizing the angiogenic switch are essential for tumor growth beyond a few millimeters. 6 Furthermore, specialization of the vasculature may even precede tumor establishment at metastatic sites. 7 These observations suggest that molecular changes in tumor vasculature might provide sensitive markers of tumor initiation or metastasis. Similarly, it is expected that genes expressed uniquely by the vasculature of tumors may provide important therapeutic targets.
Ovarian cancer critically depends on blood supply for expansive growth, and increased angiogenesis is associated with rapid tumor recurrence and decreased survival. 8, 9 Unique among solid tumors, targeting tumor angiogenesis by blocking vascular endothelial growth factor (VEGF) as monotherapy has produced tangible clinical results in ovarian cancer, [10] [11] [12] [13] [14] suggesting that vascular development is central to ovarian cancer biology. Thus, we hypothesized that ovarian cancer is an appropriate tumor to evaluate for vasculaturespecific genes to uncover novel tumor biomarkers.
To date, the expression profile of vascular cells in ovarian cancer remains unreported. We used immunohistochemistry-guided laser-capture microdissection (immuno-LCM) and transcriptional profiling 15 to characterize tumor vascular cells (TVCs) from 21 epithelial ovarian cancers and four normal ovaries. From the cancer vascular profile, we validated 12 novel tumor vascular markers (TVMs) and demonstrated that three TVMs have prognostic value. Several of these could function as tumor biomarkers or therapeutic targets; they were expressed at high levels in ovarian cancer and were either absent or expressed at significantly lower levels in normal tissues.
Primary antibodies against CD31, STC2 (Genway, San Diego, CA), F2RL1, and DR6 were incubated for 2 hours. Western blot was performed using 300 g of protein from patient sera and probed with goat antihuman DR6 antibody. All antibodies used are detailed in Table A3 (online only) .
-tumor endothelial cells (TECs) were isolated by fluorescence-associated cell sorting (FACS), after Ficol gradient centrifugation, from mechanically dispersed fresh human epithelial ovarian cancer, lung adenocarcinoma or melanoma specimens using fluorescein isothiocyanate (FITC) anti-VE-cadherin antibody (Medsystems Diagnostics, Vienna, Austria), biotinylated anti-CD146 coupled with streptavidin phycoerythrin (PE) Cy7, and APC-anti-CD45 (BD Pharmingen). 19, 20 Normal murine serum (10%; Sigma, St Louis, MO) and 25 mg/mL anti-mouse Fc receptor (BD Pharmingen) were added before incubation to avoid nonspecific binding. FACS-isolated TECs were more than 95% pure (data not shown). TECs were analyzed immediately by qRT-PCR. Human umbilical-vein endothelial cells (HUVECs) were cultured in endothelial basal medium with 10% bovine serum and 100 ng/mL VEGF. Peripheral-blood mononuclear cells (PBMCs) were obtained freshly through leukapheresis from healthy donors and analyzed immediately.
Bioinformatics and Statistical Analyses
Present/absent indicators (gene expressed/not expressed) were produced with MAS5.0 Suite (Affymetrix). All samples were normalized with the median defined as 1.0. Analysis of expression profiles used Genespring software (Agilent, Santa Clara, CA). Statistical significance for mRNA expression differences between tissue types was determined using a two-tailed t test, and differences were characterized by fold changes defined as the ratio of the normalized mean expression of the tumor to the normal vascular samples. A heat map condition tree was developed using the Genespring hierarchical clustering algorithm. Descriptive statistics were performed with SPSS statistics software (SPSS Inc, Chicago, IL). Means are presented with SEs. Nonparametric analysis based on the ranks of the expression level for tumor and normal samples was developed in SAS 9.1. 21 The log-rank statistic was used to compare the Kaplan-Meier disease-free interval (DFI) distribution of six tumors with the highest TVM expression values (highest tertile) to the remaining 11 tumors using SAS 9.1.
21

Archived Gene Expression Datasets
Data used for expression of the TVM in normal and tumor tissue samples are available via the Gene Expression Omnibus (GEO; National Center for Biotechnology Information [NCBI], http://www.ncbi.nlm.nih.gov/geo) with series numbers GSE3526 and GSE2109, respectively. All CEL files were similarly processed using the rate monotonic algorithm.
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RESULTS
Identification of TVMs
We used optimized immuno-LCM coupled with RNA amplification and genome-wide gene expression profiling 15 to profile tumor vasculature cells from 21 stage III ovarian cancers and four normal ovaries. Unsupervised hierarchical clustering was used to determine whether the transcriptional profile of microdissected TVCs differed from that of normal vascular cells. We included 17,920 genes after elimination of genes for which the difference between tumor and normal mean expression level was less than its SE. TVCs were accurately distinguished from normal vascular cells (Fig 1A) .
Seeking to identify TVMs, genes that fulfilled at least one of the following three criteria were identified (Fig 1B) : the gene was present in at least 15 of 21 TVC samples and absent in at least three of four normal vascular samples; or was present in at least 18 of 21 TVC samples and was at least three-fold overexpressed in TVC relative to normal vascular samples; or was expressed at the highest values in the TVC samples (ie, at least 20 of 21 TVC samples had higher expression values relative to normal samples). Seventy genes emerged from this analysis (Fig 1B) .
Consistent with our hypothesis that the tumor vascular profile of ovarian cancer would be distinct, several of the identified markers had not been previously reported as TVMs. We selected 12 new putative TVMs for further validation: adlican (matrix-remodeling associated 5, MXRA5); C11orf8 (metallophosphoesterase domain containing 2, MPPED2); collagen type-XI alpha-1 (COL11A1); death receptor-6 (DR6; TNF receptor superfamily member-21, TNFRSF21); epidermal growth factor-like-domain multiple-6 (EGFL6); four jointed box-1 (FJX1); coagulation factor-II (thrombin) receptor-like 1 (F2RL1); frizzled homolog-10 (FZD10); glycoprotein M6B (GPM6B); leucine zipper putative tumor suppressor-1 (LZTS1); olfactomedin-like 2B (OLFML2B); and stanniocalcin-2 (STC2). 
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Validation and Localization of TVMs
To confirm TVM expression by TVCs we immunopurified VE-cadherin
-TECs by FACS from five fresh ovarian cancer specimens. TVM mRNA expression was evaluated by qRT-PCR in TECs as well as in HUVECs and PBMCs. All TVM were detected in purified TEC, confirming the vascular origin of the genes (Fig 2A) . Adlican, C11orf8, EGFL6, FZD10, and LZTS1 were absent in HUVECs, whereas the remaining TVMs were expressed at similar or lower levels in HUVECs than in TECs. The known tumor vascular marker TEM1, tested as control, was expressed in TECs but not in HUVECs. Most TVMs were absent or expressed at the lowest level of detection in PBMCs.
ISH was used to confirm the vascular localization of those TVMs that showed relatively high expression in immunopurified TECs. Adlican, C11orf8, DR6, EGFL6, FZD10, FJX1, and GPM6B (Fig 2B; data not shown) were detected in vascular structures by ISH in five independent ovarian cancer samples. Expression was limited to small vessels except for FZD10, which was also found in larger vessels. TVMs were not detected in three independent normal ovary specimens, with the exception of FJX1, which was detected at very low levels in normal ovarian vasculature (Fig 2B; not shown) .
For several of the TVMs for which commercial antibodies are available, we performed immunofluorescence or immunohistochemistry to confirm protein expression within vascular structures. Immunofluorescence demonstrated colocalization of STC-2 with CD31 (endothelial localization; Fig 3A) . Immunohistochemistry demonstrated expression of F2RL1 in a periendothelial location and in stromal cells in tumors, whereas staining in normal ovary was rare or absent. DR6 protein was diffusely expressed in tumor vascular structures and faintly in tumor stroma. DR6 protein was expressed in the vasculature of normal ovaries, although at significantly lower levels (Fig 3B) .
Lastly, because the DR6 protein is predicted to be secreted, we performed Western blot analysis on serum from untreated patients with stage III ovarian cancer and normal controls. DR6 protein was easily detected in serum from all patients, with 3.5-fold higher levels were present in the serum of cancer patients (Fig 3C) .
Ovarian TVMs Are Novel Tumor Biomarkers
Because TVMs are expressed specifically by tumors harboring TECs, we hypothesized that TVMs could potentially function as tumor biomarkers. An important prerequisite of tumor biomarkers is that they be overexpressed in tumor relative to normal tissue from the same organ. All 12 TVMs tested were overexpressed in ovarian cancers (n ϭ 25, stage III, independent set) relative to normal ovaries (n ϭ 5; P Ͻ .05 for all TVMs) by qRT-PCR. In fact, most TVMs were expressed at the lowest limits of detection in normal ovaries (Fig 4A) .
An ideal ovarian tumor biomarker would discriminate between tumor and physiologic angiogenesis occurring in female reproductive tissues. Adlican, COL11A1, F2RL1, GPM6B, and STC2 were expressed at levels 10-to 350-fold higher in tumor versus corpus luteum, proliferative endometrium, or placenta ( Fig  4B) . However, C11orf8, EGFL6, FJX1, LZTS1, and OLFML2B, as well as TEM1, were expressed at similar levels in one or more reproductive tissues with physiologic angiogenesis and in ovarian tumors. Thus, some of the TVMs appear specific to ovarian tumor angiogenesis versus physiologic angiogenesis.
More generally, tumor biomarkers are characterized by their overexpression in tumor tissue relative to other normal tissues. Several TVMs, including adlican, COL11A1, EGFL6, F2RL1, FZD10, LZTS1, and OlfML2B showed limited or no expression by qRT-PCR in normal tissues, but were expressed at high levels in ovarian cancer. In contrast, C11orf8, DR6, FJX1, GPM6B, and STC2 were expressed in at least one normal tissue ( Fig 4C) .
As an independent analysis, we examined the expression profile of TVMs in normal tissues in a publicly available gene expression profile data set that included 44 normal tissue types from five male and five female human donors. Results were concordant with the above qRT-PCR data, showing little or no TVM expression in normal ovary (Fig 5A). C11orf8, CL11A1, EGFL6, FJX1, F2RL1, FZD10 , LZTS1, and STC2 were also absent in almost all normal human tissues, with few exceptions. Adlican, DR6, and GPM6B were detected in many normal tissues including reproductive organs and the nervous system. Similar results were obtained using publicly available serial analysis of gene expression (SAGE) data sets (data not shown).
Expression Profile of TVMs in Tumors
We evaluated whether TVMs identified in ovarian cancer are also expressed in other tumors using data from a publicly available data set with 755 cancer specimens from 22 different organ sites. All TVMs were overexpressed in ovarian cancer relative to normal ovary. Select TVMs such as adlican, COL11A1, DR6, F2RL1, and GPM6B were overexpressed in the majority of tumors (Fig 5B) . Significant variability in expression of the remaining TVMs was detected among tumors.
We independently tested expression of TVM by qRT-PCR in lung cancer, mesothelioma, breast cancer, melanoma, and ovarian cancer (Fig 6A) . As expected, most TVMs were expressed at quantitatively different levels in different types of malignancy. These differences persisted when expression was normalized to CD31 or VE-cadherin, to control for vascular density.
TVMs Are Expressed by TECs in Other Tumors
Given the heterogeneity of expression of TVMs among tumors, we tested whether TECs from different tumors express TVMs at different levels. We FACS purified VE-cadherin
-tumor endothelial cells from melanoma (n ϭ 4), lung cancer (n ϭ 4), and ovarian cancer (n ϭ 5) and analyzed TVMs by qRT-PCR. As expected, we observed significant quantitative differences of TVM expression among tumor types. For example, adlican and EGFL6 were primarily expressed in ovarian TECs. Lung TECs expressed COL11A1, DR6, F2RL1, and STC2. Melanoma TECs expressed most TVMs, but not adlican, EGFL6, and STC2 (Fig 6B) .
TVMs Are Prognostic Markers
Finally for each TVM, the Kaplan-Meier DFI distributions were computed for patients with high TVM expression (in the highest tertile of TVM expression in microdissected TVCs) compared with those with lower TVM expression (Fig 6C) . The expression of STC2, EGFL6, and FZD10 in the highest tertile was associated with significantly decreased DFI (all P Ͻ .005). By contrast, the survival curves of patients with highest tertile and lower expression of the vascular markers CD31 and VE-cadherin were not significantly different (not shown), suggesting that the observed effect with TVMs is not simply a result of increased content of endothelial cells. 
DISCUSSION
This study identified for the first time the expression profile of ovarian cancer vasculature in situ, and showed that high-throughput genome-wide discovery efforts addressing tumor vasculature can unveil interesting candidate genes for further testing as tumor biomarkers or therapeutic targets. The immuno-LCM isolation used in this study has the advantage of capturing TECs in their natural microenvironment, and, on the basis of the use of frozen samples, allowed us to analyze the largest number of samples to date in tumor vasculature profiling. Our protocol also allows for the inclusion of pericytes, and our work suggests that pericytes are likely to be one source of TVMs. Seventy genes were identified as TVMs including several known TVMs or TVM family members. We validated 12 novel TVMs; these were expressed by immunopurified TECs, and expression in vivo was localized to vascular structures. Thus, the approach undertaken was robust and can provide a detailed molecular map of tumor vasculature. Although ovarian vascular cells expressed numerous genes identified in other tumor vascular profiles, including several collagen molecules, nidogen 2, Thy-1, FolH1, and TEM7, the majority of the TVMs identified have not been reported in vascular profiling studies from colon cancer, glioblastoma multiforme, or breast ductal carcinoma in situ. 4, 23, 24 This could be due in part to differences in the techniques utilized, the number of samples analyzed, or true heterogeneity of vascular endothelium among tumors. Analysis of TVM expression from immunopurified TVCs from ovarian cancer, lung cancer, and melanoma suggested significant quantitative differences among TVCs from the three tumor types. These results argue that the distinct molecular profiles observed to date are due in part to TEC specialization in different tumor types.
Many of the TVMs identified were markedly overexpressed in ovarian cancer relative not only to normal ovary but also to a comprehensive panel of normal organs. By highly sensitive qRT-PCR, adlican, COL11A1, EGFL6, F2RL1, FZD10, LZTS1, and OlfML2B were detected at the lowest limits, or not at all, in normal tissues tested. These findings were confirmed by SAGE data and by comprehensive gene expression array data including 44 different normal tissues. Thus, some of the TVMs validated may be considered for further preclinical testing as bona fide tumor biomarkers or therapeutic targets. Our Western blot analysis suggests that secreted proteins such as DR6, adlican, and COL11A1 could provide useful serum tumor biomarkers. More sensitive/quantitative enzyme-linked immunosorbent assay analyses are necessary to test this in a larger population of patients.
Sensitive antibodies could detect nascent tumors or monitor small changes in tumor status. Similarly, surface proteins expressed by TECs, such as TNFRSF21, may circumvent existing biodistribution barriers of tumors and function as useful targets for cancer antibodybased therapy or molecular imaging. Importantly, some of the TVMs identified here were not expressed by reproductive tissues that exhibit increased angiogenesis, such as placenta, corpus luteum, or proliferative endometrium. This is a critical feature to enhance specificity in reproductive-age women requiring surveillance because of a hereditary risk of ovarian cancer.
Some of the TVMs identified in ovarian cancer were expressed in a variety of other tumors. Thus, diagnostic or therapeutic tools developed on the basis of such TVMs may be applicable to several tumor types. The use of large gene expression array databases can significantly accelerate mapping of these markers in different tumor types to select disease targets for further clinical validation. Importantly, we found that overexpression of select TVMs in purified vascular cells was significantly predictive of poor clinical outcome. Because some of these TVMs are expressed in other tumor types, their prognostic potential may be applicable to other tumors. These data confirm our hypothesis that tumor vascular proteins can provide novel biomarkers, which could aid in early tumor detection or prognosis. Additional studies will be required to determine the clinical relevance of the biomarkers identified.
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